Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

Immunofoco announced Phase I/IIa clinical data for IMC002, a CLDN18.2-targeted CAR-T therapy, at ASCO GI 2026.

Data highlighted a durable complete response exceeding one year.

Achieved an objective response rate (ORR) of 66.7% in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJ).

Immunofoco is a clinical-stage biotech company developing CAR-T therapies for solid tumors.

Prior Phase I data showed no dose-limiting toxicities, good safety, and preliminary efficacy in advanced gastric and pancreatic cancers.1

Sources: